AAIC 2026: Latin FINGERS Prevention Network and Real-World Data on Anti-Amyloid Immunotherapies
Latin FINGERS has produced significant prevention research across multiple Latin American countries and built a multinational researcher network and infrastructure that speakers called an unprecedented opportunity for prevention in the region. AAIC 2026 also highlights how the approved anti-amyloid immunotherapies lecanemab and donanemab perform in real clinical settings rather than controlled trials, adding evidence on whether they translate to practice. The coverage sits at the intersection of public health and neuroscience, focusing on prevention infrastructure and real-world evidence for marketed disease-modifying therapies.
Prevention network: Latin FINGERS has not only produced significant prevention research across multiple Latin American countries, but has also built a multinational researcher network and infrastructure; the speaker called it an "unprecedented" opportunity for prevention in Latin America.; Drug pipeline: Alzheimer's drug development has long been disappointing, until recently when two anti-amyloid immunotherapies, lecanemab and donanemab, were approved in multiple countries; they can clear amyloid plaques in the brain and slow (not cure) the disease.; Real world: AAIC 2026 focuses on how these drugs perform in real clinical settings (rather than strictly controlled trials), filling in evidence on whether they "work in practice".; Positioning: Conference coverage / public health–neuroscience intersection, focusing on prevention infrastructure and real-world evidence of approved disease-modifying therapies.
- Prevention network: Latin FINGERS has not only produced significant prevention research across multiple Latin American countries, but has also built a multinational researcher network and infrastructure; the speaker called it an "unprecedented" opportunity for prevention in Latin America.
- Drug pipeline: Alzheimer's drug development has long been disappointing, until recently when two anti-amyloid immunotherapies, lecanemab and donanemab, were approved in multiple countries; they can clear amyloid plaques in the brain and slow (not cure) the disease.
- Real world: AAIC 2026 focuses on how these drugs perform in real clinical settings (rather than strictly controlled trials), filling in evidence on whether they "work in practice".
- Positioning: Conference coverage / public health–neuroscience intersection, focusing on prevention infrastructure and real-world evidence of approved disease-modifying therapies.
Source: YouTube